Standard BioTools Delays Quarterly Report Filing

Standard BioTools ( (LAB) ) has released a notification of late filing.

Standard BioTools Inc. has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending June 30, 2025. The delay is primarily due to the time required to complete financial closing procedures and finalize adjustments necessary to reflect the disposal group as discontinued operations. This is related to a stock purchase agreement entered into on June 22, 2025, for the sale of its subsidiaries, SomaLogic, Inc., Sengenics Corporation LLC, and Sengenics Corporation Pte Ltd. The company expects to file the report within the five-day extension period allowed under Rule 12b-25. There is an anticipation of significant changes in financial results from the previous year, although specific details are not provided. Forward-looking statements are included, indicating potential risks and uncertainties. Standard BioTools is actively working on compliance and the notification is signed by Alex Kim, the Chief Financial Officer.

The most recent analyst rating on (LAB) stock is a Buy with a $2.75 price target. To see the full list of analyst forecasts on Standard BioTools stock, see the LAB Stock Forecast page.

Spark’s Take on LAB Stock

According to Spark, TipRanks’ AI Analyst, LAB is a Neutral.

Standard BioTools’ overall stock score is primarily influenced by its financial challenges and valuation concerns, which are offset by positive corporate events and strategic initiatives. The company’s efforts to streamline operations and improve cash reserves are promising, but profitability remains a key concern.

To see Spark’s full report on LAB stock, click here.

More about Standard BioTools

Average Trading Volume: 1,892,107

Technical Sentiment Signal: Sell

Current Market Cap: $486.2M

For detailed information about LAB stock, go to TipRanks’ Stock Analysis page.